MAAT PHARMA SACA (MAAT.PA) Stock Income Statement
Europe - Euronext Paris - EPA:MAAT - FR0012634822 - Common Stock
4 EUR
+0.03 (+0.76%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.92M | 3.22M | 2.23M | 1.43M | 972.00K | |||
| Cost Of Goods | 1.50M | 1.25M | 573.00K | 339.00K | 166.00K | |||
| Gross Profit | 2.42M | 1.97M | 1.66M | 1.09M | 806.00K | |||
| Operating Expenses | 32.84M | 30.39M | 21.60M | 14.65M | 9.70M | |||
| Research and Development | 29.39M | 27.30M | 20.85M | 14.31M | 9.14M | |||
| Selling, General, and Administrative Expenses | 7.84M | 6.92M | 5.41M | 4.46M | 2.94M | |||
| Operating Income | -30.42M | -28.43M | -19.94M | -13.56M | -8.89M | |||
| Interest Income/Expense | -1.03M | -868.00K | -402.00K | -140.00K | -121.00K | |||
| Other Income/Expense | 317.00K | 391.00K | 628.00K | -16.00K | -5.00K | |||
| Income Before Taxes | -31.13M | -28.91M | -19.72M | -13.71M | -9.02M | |||
| Net Income | -31.13M | -28.90M | -19.72M | -13.71M | -9.02M | |||
| EBITDA | -28.70M | -26.74M | -19.07M | -13.13M | -8.56M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.15 | -2.21 | -1.73 | -1.39 | -0.91 | |||
| Statistics | ||||||||
| Gross Profit Margin | 61.68% | 61.13% | 74.28% | 76.29% | 82.92% | |||
| Profit Margin | -793.80% | -898.76% | -884.96% | -958.95% | -927.88% | |||
| Operating Profit Margin | -775.65% | -883.96% | -895.11% | -948.04% | -914.92% | |||
All data in EUR